Drugs with novel mechanisms of inhibiting angiogenesis are beginning to emerge in company pipelines. Espicom has identified 13 major projects in Phase III development, with a further 10 in Phase II. Novel agents include:
Enzastaurin: A novel agent that acts through inhibition of protein kinase C and has been found to suppress tumour growth through multiple mechanisms, such as the direct suppression of tumour cell proliferation.
Panobinostat: This pan-histone deacetylase inhibitor targets multiple oncogenic pathways, including angiogenesis.
PF-02341066: This is a selective ATP-competitive small-molecule inhibitor of both c-Met/hepatocyte growth factor receptor and anaplastic lymphoma kinase tyrosine kinases and their oncogenic variants.
With this report you will...
Understand Avastin's unique position in the oncology market
Evaluate its strengths and weaknesses relative to other VEGF-targeting products
Gain insight into the prevalence of cancers in Avastin's therapeutic window
Review the merits of 21 late-phase development prospects with Espicom's unique 5-point competitive assessment
Know the launch timeframe for up and coming products
Estimate future revenues with 5-year forecasts for more than 20 launched and late-phase products
Just some of the approaches being used by products in this report
VEGFr-1, -2 and -3 tyrosine kinase inhibitors
MET & RET inhibitors
Questions answered by the report include...
Which other products in the pipeline mirror Avastin's therapeutic approach?
What are the extension indications Avastin is expected to secure to 2016?
In 2012, five products targeting the VEGF pathway are expected to lau
Copyright©2010 PR Newswire.
All rights reserved